Therapeutic Cancer Vaccines: The failures

Cancer immunotherapy and cancer vaccines were named Science Magazine’s ‘Breakthrough of the Year 2013‘, but whilst the industry continues to be optimistic about the promises of harnessing a patients immune system to treat cancer, it’s hard to ignore the big disappointments that have been recorded in a number of high profile Phase III and II trial failures. Here are just …

Winner of the Best #Vaccine Licensing Deal: Vical and @astellas @ #wvcusa ViE Awards

The Best Vaccine Licensing Deal category was open to pharma, biotech and academic stakeholders within the vaccine industry that had engaged in a two-way licensing deal for a vaccine candidate or technology within the last 12 months. The criteria used to judge this category will be as follows: The structure of the deal, the involved parties, the candidate in question …